EUVIMEDEUVIMED entdecken
Systematische ÜbersichtOpen Access · CC BY-NC-ND 4.0

Treatment approaches and outcomes in interstitial pneumonia with autoimmune features (IPAF): a systematic review

Jairo Cajamarca-Baron, Juan Pablo Castañeda-Gonzalez, Diana Guavita-Navarro, Andres Lamos-Duarte, Jose Yate, Alejandro Escobar, Adriana Rojas-Villarraga

Global Rheumatology · 11.11.2026

DOI: 10.46856/grp.2026.0012 ↗

Kurz gefasst

Systematische Übersicht in der Zeitschrift Global Rheumatology, online erschienen am 11.11.2026. Verfasst von Jairo Cajamarca-Baron und 6 weiteren Autor:innen. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

Interstitial lung disease (ILD) encompasses various parenchymal disorders, including those with autoimmune features not meeting CTD criteria, termed Interstitial Pneumonia with Autoimmune Features (IPAF).

Objectives

To systematically review treatment strategies and outcomes in patients with IPAF, and to describe baseline patient characteristics reported in treatment studies. Methodology A systematic review followed PRISMA guidelines (PROSPERO: CRD42023443823). PubMed and EMBASE were searched through December 2022 for IPAF treatment studies. Data were extracted on clinical, serologic, and morphologic domains, treatments, comorbidities, and outcomes as reported in studies evaluating IPAF treatment. Quality was assessed using JBI tools.

Results

Out of 217 articles, 32 met inclusion criteria, covering 1,500 patients. Most were women (62.8%) with a mean age of 57.4 years. Symptoms included cough (66.7%) and dyspnea (55.1%). ANA (54.4%) and anti-Ro (29.5%) were the most frequent serologic markers, and NSIP (55.2%) predominated morphologically. Glucocorticoids (69.4%) and mycophenolate (9.7%) were commonly prescribed, with inconsistent responses. FVC improvement was noted in some cohorts. Comorbidities included hypertension, GERD, and smoking (27%).

Conclusions

The heterogeneity observed among IPAF patients included in treatment studies highlights the need for standardized guidelines and randomized trials to refine management strategies.

Zitieren

APA

Cajamarca-Baron, J., Castañeda-Gonzalez, J. P., Guavita-Navarro, D., Lamos-Duarte, A., Yate, J., Escobar, A., & Rojas-Villarraga, A. (2026). Treatment approaches and outcomes in interstitial pneumonia with autoimmune features (IPAF): a systematic review. Global Rheumatology. https://doi.org/10.46856/grp.2026.0012

Vancouver

Cajamarca-Baron J, Castañeda-Gonzalez JP, Guavita-Navarro D, Lamos-Duarte A, Yate J, Escobar A, et al. Treatment approaches and outcomes in interstitial pneumonia with autoimmune features (IPAF): a systematic review. Global Rheumatology. 2026. doi:10.46856/grp.2026.0012

BibTeX
@article{CajamarcaBaron2026,
  author = {Cajamarca-Baron, Jairo and Castañeda-Gonzalez, Juan Pablo and Guavita-Navarro, Diana and Lamos-Duarte, Andres and Yate, Jose and Escobar, Alejandro and Rojas-Villarraga, Adriana},
  title = {Treatment approaches and outcomes in interstitial pneumonia with autoimmune features (IPAF): a systematic review},
  journal = {Global Rheumatology},
  year = {2026},
  doi = {10.46856/grp.2026.0012}
}
Kostenlos starten →